At its Meeting on 23 May 2022, the Transparency Council adopted Position No. 45/2022 on the assessment of the legitimacy of changing PET/MRI medical technology using [18F] FDG or 18F-florbetapir or 18F-flutemetamol or 18F-florbetaben for neurological indications.